SCHEMBL156248

SCHEMBL156248

CCC(C)(C)c1ccc(C=CC(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.52
ESR2 Q92731 4/20 0.52
HCAR2 Q8TDS4 2/20 0.52
CA12 O43570 2/20 0.52
AKR1B10 O60218 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA3 P07451 2/20 0.52
AKR1B1 P15121 2/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
DPP4 P27487 2/20 0.52
CA5A P35218 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA14 Q9ULX7 2/20 0.52
CA5B Q9Y2D0 2/20 0.52
PKM P14618 1/20 0.52
TYR P14679 1/20 0.52
CYP1A2 P05177 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17434615 0.83 ESR1 (0.49) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL4001354 0.82 CYP1A2 (0.75) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL818742 0.82 CYP1A2 (0.75) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL846833 0.82 CYP1A2 (0.75) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL6570565 0.82 HCAR2 (0.59) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL847387 0.81 CA12 (0.65) ESR1CA12CA1CA2DPP4
SCHEMBL847388 0.81 CA12 (0.65) ESR1CA12CA1CA2DPP4
SCHEMBL4575016 0.79 HCAR2 (0.55) ESR1ESR2HCAR2CA12AKR1B10
SCHEMBL25200098 0.79 MAOB (0.63) ESR1ESR2CA1CA2MAPK1
SCHEMBL25574505 0.79 MAOB (0.63) ESR1ESR2CA1CA2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160128944-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME VYOME THERAPEUTICS LIMITED (IN) 2016-05-12 US claimed
EP-3003031-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME Vyome Biosciences Pvt Ltd (IN) 2016-04-13 EP claimed
WO-2014195872-A1 COATED PARTICLES AND COMPOSITIONS COMPRISING SAME VYOME BIOSCIENCES PVT. LTD. (IN) 2014-12-11 WO claimed
US-8404258-B2 External preparation for the skin SHISEIDO COMPANY, LTD. (JP) 2013-03-26 US claimed
EP-3714863-B1 COSMETIC SAKAI CHEMICAL INDUSTRY CO (JP) 2024-07-17 EP disclosed
CN-118338957-A Oil-in-water type composition 株式会社资生堂 2024-07-12 CN disclosed
CN-113164433-B Oily moisturizer and external composition for skin containing same 日清奥利友集团株式会社 2024-07-09 CN disclosed
US-20240216239-A1 LIQUID OILY COMPOSITION AND COSMETIC CONTAINING SAME THE NISSHIN OILLIO GROUP, LTD. (JP) 2024-07-04 US disclosed
WO-2024142841-A1 COMPOSITION 株式会社 資生堂 2024-07-04 WO disclosed
WO-2024142969-A1 WATER-IN-OIL EMULSION COMPOSITION 株式会社 資生堂 2024-07-04 WO disclosed
WO-2024142892-A1 W/O/W EMULSIFIED COMPOSITION 株式会社 資生堂 2024-07-04 WO disclosed
CN-118234468-A Cosmetic product 株式会社资生堂 2024-06-21 CN disclosed
EP-0728469-A2 An endermic liniment SHISEIDO COMPANY LIMITED (JP) 1996-08-28 EP disclosed
EP-0697212-A2 Deodorant cosmetic composition superior in resistance to discoloration and dispersion SHINAGAWA FUEL CO., LTD. (JP) 1996-02-21 EP disclosed
EP-0487404-B1 External dermatological composition HAYASHIBARA BIOCHEM LAB (JP) 1995-10-11 EP disclosed
US-5310730-A Containing glycoside of hydroquinone, alcohol, surfactant, oil and water or wax; depigmenting, nonirritating SHISEIDO COMPANY LTD. (JP) 1994-05-10 US disclosed
EP-0570230-A1 External preparation for skin SHISEIDO COMPANY LIMITED (JP) 1993-11-18 EP disclosed
EP-0487404-A1 External dermatological composition KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 1992-05-27 EP disclosed
US-5053222-A Antidandruff agents SHISEIDO COMPANY LTD. (JP) 1991-10-01 US disclosed
US-4764505-A GLYCOSIDE OF HYDROQUINONE-SUPPRESSION OF SKIN IRRITATION SHISEIDO COMPANY LTD. (JP) 1988-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216239-A1 LIQUID OILY COMPOSITION AND COSMETIC CONTAINING SAME MGLL, MSMO1, TP53RK ESR1 2188/4885ESR2 2371/4885HCAR2 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.